This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Xilis Inc., a for-profit manufacturing organization. The contract is for the development of tissue-derived droplet micro-organospheres as models for high-throughput testing of pathogens, with a total potential value of $224,658.00. The contract has a firm fixed price pricing type and a completion date of August 31, 2021. The original solicitation was a Broad Agency Announcement from DARPA seeking proposals for SBIR and Small Business Technology Transfer (STTR) funding opportunities to advance DARPA's mission across various technical domains.
Generated 3/22/24, 12:18 AM